Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.
The PEARLS study prospectively monitored selected nosocomial pathogens from 38 centres in 13 European, three Middle Eastern countries and South Africa during 2001-2002. Extended spectrum beta-lactamase (ESBL) production rates among Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp. were 5.4% (142/2609), 18.2% (401/2,206) and 8.8% (204/2,328), respectively, for all study sites. The overall ESBL production rate for the combined Enterobacteriaceae was 10.5% (747/7,143), highest in Egypt, 38.5%, and Greece, 27.4%, and lowest in The Netherlands, 2.0%, and Germany, 2.6%. IEF, PCR and DNA sequencing determined 10.7% false positives among Enterobacter spp. when using NCCLS guidelines to screen for ESBL production. The prevalence of nosocomial methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium was 32.4% (294/908) and 8.7% (83/949), respectively. PEARLS provides baseline data against which prospective changes in resistant determinants and outcomes can be measured in this ongoing study.
Bouchillon
S K
SK
Laboratories International for Microbiology Studies, 2122 Palmer Road, Schaumburg, IL 60173-3817, USA. sambouchillon@comcast.net
Johnson
B M
BM
Hoban
D J
DJ
Johnson
J L
JL
Dowzicky
M J
MJ
Wu
D H
DH
Visalli
M A
MA
Bradford
P A
PA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology; D004756:Enterobacteriaceae Infections / Q000453:epidemiology* / Q000382:microbiology; D016984:Enterococcus faecium / Q000187:drug effects*; D005060:Europe / Q000453:epidemiology; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D015994:Incidence; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008877:Middle East / Q000453:epidemiology; D011159:Population Surveillance; D013019:South Africa / Q000453:epidemiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D020713:Vancomycin Resistance; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases